Published in Nat Biotechnol on February 01, 2009
MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell (2010) 3.28
A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol (2011) 1.38
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (2010) 1.36
Landmark approval for Dendreon's cancer vaccine. Nat Biotechnol (2010) 1.35
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26
Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol (2013) 1.12
Translational medicine--doing it backwards. J Transl Med (2010) 1.03
Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des (2012) 1.00
Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. Clin Exp Immunol (2009) 0.98
Recent Development in Carbohydrate Based Anti-cancer Vaccines. J Carbohydr Chem (2012) 0.98
Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv Drug Deliv Rev (2012) 0.97
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology (2012) 0.97
Cancer vaccines. Philos Trans R Soc Lond B Biol Sci (2011) 0.91
Is cancer gene therapy an empty suit? Lancet Oncol (2013) 0.90
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 0.89
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice. Eur J Immunol (2010) 0.84
Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res (2010) 0.83
Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer. Semin Immunopathol (2016) 0.83
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer. Int J Cancer (2012) 0.82
Lung cancer vaccines. Cancer J (2011) 0.82
Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions. MAbs (2011) 0.80
Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives. Front Pediatr (2013) 0.78
Is cancer vaccination feasible at older age? Exp Gerontol (2014) 0.77
Cancer genome sequencing and its implications for personalized cancer vaccines. Cancers (Basel) (2011) 0.75
Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines. J Control Release (2017) 0.75
The tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced efficacy by the protein component from Agrocybe aegerita. Int J Clin Exp Med (2015) 0.75
Regulation of the IL-10-driven macrophage phenotype under incoherent stimuli. Innate Immun (2016) 0.75
Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther (2014) 0.75
Overview of cancer vaccines: considerations for development. Hum Vaccin Immunother (2012) 0.75
The role of glycans in immune evasion: the human fetoembryonic defence system hypothesis revisited. Mol Hum Reprod (2013) 0.75
An empiric victory. Nat Biotechnol (2010) 0.75
State of the art in tumor antigen and biomarker discovery. Cancers (Basel) (2011) 0.75
Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses. PLoS One (2017) 0.75
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol (2005) 2.64
Trouble at the office. Nat Biotechnol (2008) 2.12
Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J (2002) 1.15
Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res (2006) 1.03
L-type Ca2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res (2002) 2.62
Reproductive medicine: the first cut. Nature (2007) 1.48
23andMe's designer baby patent. Nat Biotechnol (2014) 1.40
Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry (2014) 1.40
The paper trail to commercialization. Nat Biotechnol (2007) 1.39
Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network. Contemp Clin Trials (2011) 1.38
Landmark approval for Dendreon's cancer vaccine. Nat Biotechnol (2010) 1.35
Sequencing firms eye pathology labs as next big market opportunity. Nat Biotechnol (2011) 1.22
Texas legitimizes path around FDA oversight. Nat Biotechnol (2012) 1.11
Adult stem cell therapies walk the line. Nat Biotechnol (2012) 1.03
CAR-T cell therapy seeks strategies to harness cytokine storm. Nat Biotechnol (2014) 1.02
Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis (2008) 1.02
Life Technologies promises $1,000 genome. Nat Biotechnol (2012) 1.00
Multidrug resistance: can new drugs help chemotherapy score against cancer? J Natl Cancer Inst (2003) 0.99
Seattle Genetics rare cancer drug sails through accelerated approval. Nat Biotechnol (2011) 0.94
Perineal muscles and motoneurons are sexually monomorphic in the naked mole-rat (Heterocephalus glaber). J Neurobiol (2002) 0.91
Characteristics of an outpatient treatment sample by primary substance of abuse. J Addict Med (2013) 0.90
Cancer vaccines: finding the best way to train the immune system. J Natl Cancer Inst (2002) 0.89
Public biotechnology 2002--the numbers. Nat Biotechnol (2003) 0.88
Five more years of Nature Biotechnology research. Nat Biotechnol (2011) 0.88
Juno's wild ride. Nat Biotechnol (2016) 0.87
Little science, big bucks. Nat Biotechnol (2003) 0.84
Dynavax trial halted. Nat Biotechnol (2008) 0.83
For investigational targeted drugs, combination trials pose challenges. J Natl Cancer Inst (2003) 0.80
Lethal vertebral artery dissection in pregnancy: a case report and review of the literature. Arch Pathol Lab Med (2006) 0.79
RIP Raptiva? Nat Biotechnol (2009) 0.79
Protein kinase Cβ is required for lupus development in Sle mice. Arthritis Rheum (2013) 0.78
Omics gets personal. Nat Biotechnol (2012) 0.77
Vintage genetic engineering. Nat Biotechnol (2008) 0.76
Combinations of targeted therapies take aim at multiple pathways. J Natl Cancer Inst (2003) 0.76
The faking of champions. Nat Biotechnol (2004) 0.76
DNA goes to court. Nat Biotechnol (2012) 0.75
23andMe protects consumers' data. Nat Biotechnol (2015) 0.75
Chimera research under the spotlight. Nat Biotechnol (2016) 0.75
US Congress moves to 'protect' GM crop plantings. Nat Biotechnol (2013) 0.75
Erratum: 20 years of Nature Biotechnology research tools. Nat Biotechnol (2016) 0.75
Real-time PCR takes center stage. Anal Chem (2003) 0.75
Erratum: Nature Biotechnology's academic spinouts of 2016. Nat Biotechnol (2017) 0.75
California cracks down on stem cell cowboys. Nat Biotechnol (2017) 0.75
Timothy J. Bartness. J Biol Rhythms (2016) 0.75
Erratum: Drug pipeline: 2Q15. Nat Biotechnol (2015) 0.75
CAR-T's forge ahead, despite Juno deaths. Nat Biotechnol (2017) 0.75
Drug pipeline: Q312. Nat Biotechnol (2012) 0.75
Throwing money at biodefense. Nat Biotechnol (2004) 0.75
Erratum: Selling long life. Nat Biotechnol (2015) 0.75
Profile: Rade Drmanac. Nat Biotechnol (2008) 0.75
Good drug, bad luck: business, regulatory issues can create obstacles for drug development. J Natl Cancer Inst (2004) 0.75
Company founders: voices of experience. Nat Biotechnol (2004) 0.75
Taming a mutinous mutant: an errant receptor becomes a prime cancer target. J Natl Cancer Inst (2007) 0.75
Hypertrophic cardiomyopathy with features of left ventricular non-compaction: how many diseases? Int J Cardiol (2011) 0.75
The 'anti-hype' vaccine. Nat Biotechnol (2017) 0.75
Zika pipeline progresses. Nat Biotechnol (2016) 0.75
Drug pipeline: 1Q13. Nat Biotechnol (2013) 0.75
Drug pipeline: Q212. Nat Biotechnol (2012) 0.75
Profile: Lisa Drakeman. Nat Biotechnol (2005) 0.75
Ebola vaccine trial falls short of homerun. Nat Biotechnol (2015) 0.75
Hanging on a thread. Nat Biotechnol (2017) 0.75
Next generation of targeted radiotherapy drugs emerging from the clinical pipeline. J Natl Cancer Inst (2004) 0.75
The SEC need for speed. Anal Chem (2002) 0.75
Corrigendum: Selling long life. Nat Biotechnol (2015) 0.75
Consortium nurtures ex vivo gene therapy firm. Nat Biotechnol (2016) 0.75
IOM smacks down California Institute of Regenerative Medicine. Nat Biotechnol (2013) 0.75
Masters of their universe. Nat Biotechnol (2009) 0.75
What's app? Helix wants you to quiz your genome-some of it for fun. Nat Biotechnol (2017) 0.75
Erratum: Nature Biotechnology's academic spinouts of 2015. Nat Biotechnol (2016) 0.75